Metastatic prostate cancer patients present in two ways—with already disseminated disease
at the time of presentation or with disease recurrence after definitive local therapy. Androgen …

Docetaxel in combination with prednisone is the standard of care in men with symptomatic
castration-resistant prostate cancer (CRPC). However, a substantial proportion of men with …

Background The tumors of many patients with prostate cancer eventually become refractory
to androgen deprivation therapy with progression to metastatic castration-resistant disease …

The management of metastatic prostate cancer (mPCa) has changed over the past ten
years. Several new drugs have been approved with significant overall survival benefits in …

Purpose: The availability of newly approved treatment options for metastatic castration
resistant prostate cancer is not matched with conclusive data on optimal sequencing …

Metastatic castration resistant prostate cancer (CRPC) is an inevitably fatal disease.
However, in recent years, several treatments have been shown to improve the outcome of …

Background Treatment of poor prognosis metastatic castration-resistant prostate cancer
(mCRPC) includes taxane chemotherapy and androgen receptor pathway inhibitors (ARPI) …

Most men with recurrent prostate cancer (CaP) initially respond to androgen deprivation
therapy but eventually develop metastatic castration-resistant prostate cancer (CRPC). Over …

Taxanes–docetaxel and cabazitaxel–are the most active chemotherapy drugs currently used
for the treatment of metastatic castration-resistant prostate cancer (mCRPC). However …

Context Until recently, the only approved agent for metastatic castration-resistant prostate
cancer (mCRPC) was docetaxel chemotherapy. But over the last 5 years, significant …